Estimated costs of production and potential prices for the WHO Essential Medicines List

by Andrew M Hill, Melissa J Barber, Dzintars Gotham
BMJ Glob Health 2018;3:e000571 – Published 29 January 2018

8 pp. 1.1 MB

There are persistent gaps in access to affordable medicines. The WHO Model List of Essential Medicines (EML) includes medicines considered necessary for functional health systems. The authors conclude that a wide range of medicines in the EML can be profitably manufactured at very low cost. Most EML medicines are sold in the UK and South Africa at prices significantly higher than those estimated from production costs. Generic price estimation and international price comparisons could empower government price negotiations and support cost-effectiveness calculations.

The full list of estimated ‘cost-based prices’ can be downloaded from the supplementary appendix linked here:

(Visited 25 times, 1 visits today)
This entry was posted in Essential Medicines, General, Global Health. Bookmark the permalink.